- PLN124.93m
- PLN143.63m
- PLN15.76m
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys
Brief: Mabion Signs Loan Agreement With CBC Co. For Up To EUR 3.1 Mln
Brief: Mabion Q3 Net Loss 10.8 Mln Zlotys
Brief: Mabion Updates Strategy For 2025-2030
Brief: Mabion Q2 Net Loss At 15.4 Million Zlotys
Brief: Mabion Q2 Net Loss At 15.4 Million Zlotys
Brief: Mabion Receives Term Sheet From Twiti Investments
Brief: Mabion Appoints Gregor Kawaletz As CEO
Brief: Mabion Director For Business Development Adam Pietruszkiewicz Resigns From Management Board
Brief: Novalgen To Begin World’s First Clinical Trial For A Self-Regulating Immunotherapy
Brief: Mabion Says Krzysztof Kaczmarczyk Dismissed As CEO
Brief: Mabion Signs New Deal With Brazil's IBMP For Drug Manufacturing Technology Transfer
Brief: Mabion Says Conditions For Order From IBMP Get Fulfilled
Brief: Mabion Says Delivery Date Extended To Q4 Under Annex To Deal With Bonfiglioli Engineering
Brief: Mabion Q1 Net Loss 15.3 Mln Zlotys
Brief: Mabion Fulfills Condition For Deal With WPD Pharmaceuticals